Viatris spent a good chunk of its recent investor day updating on its complex generics ambitions, especially considering it is set to be missing biosimilars from its armory in the back half of 2022. A proposed move for the first US generic Symbicort was suggested by management.
One facet of Viatris’ business plan for the years ahead remains clear, after it announced the proposed sale of its global biosimilars business to long-time partner Biocon Biologics.
A commitment to continue to expand in complex generics was reiterated by management during the firm’s recent virtual investor event,
Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.
Gedeon Richter’s CEO has urged analysts and the firm itself to give more attention to its “unfairly neglected” General Medicines division – which includes both generics and licensed-in innovative products – during the Hungarian firm’s first-quarter earnings call.
With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.
As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.
As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.
Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.
A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.
